Canadian Cancer Trials Group Bulletins


ASCO 2010 Highlights

Interim results of the Canadian Cancer Trials Group's PR.3 study -- Intergroup Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Adenocarcinoma of the Prostate -- show that combining radiation and hormone therapy in patients with high risk prostate cancer significantly improves the likelihood of patients living longer.

Dr. Padraig Warde, the trial chair, presented these results in an oral presentation during the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago this past weekend.

Results of the trial received widespread media coverage including on the CBC, Global National, and the New York Times.

Additionally, Dr. Elizabeth Eisenhauer was the "discussant" (i.e. provided the public commentary) for a session discussing the results of an ovarian trial which showed that bevacizumab prolongs progression-free survival for women with advanced ovarian cancers.

Links to some of this media coverage are provided below:

New York Times: